Cendakimab
- Generic Name
- Cendakimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- O8R9U9ZUVN
- Background
Cendakimab is a recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT05638282
- Locations
- 🇨🇳
Local Institution - 0001, Guangzhou, Guangdong, China
A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 104
- Registration Number
- NCT05337345
- Locations
- 🇺🇸
Anaheim Clinical Trials Llc, Anaheim, California, United States
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT05175352
- Locations
- 🇺🇸
Local Institution - 021, Plantation, Florida, United States
🇺🇸Local Institution - 012, Columbus, Ohio, United States
🇺🇸Local Institution - 001, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath